April 24, 2019 / 6:09 AM / 3 months ago

BRIEF-Novartis CEO Says Zolgensma "on track" as May approval date approaches

April 24 (Reuters) - Novartis AG:

* CEO SAYS APPROVAL OF ZOLGENSMA GENE THERAPY "ON TRACK" FOR MAY, TAKING ICER REVIEW INTO ACCOUNT WHEN DECIDING ON PRICE

* CEO SAYS FOCUS IS TO TRANSFORM SANDOZ UNDER NEW LEADER, CONTINUE TO MAKE IT AUTONOMOUS WITHIN NOVARTIS

* CEO SAYS LEGAL DISPUTE WITH AMGEN BASED ON "DIFFERENT UNDERSTANDINGS", HOPES TO COME TO A CONCLUSION IN THE COMING YEARS; "IN THE MEANTIME, IT'S BUSINESS AS USUAL"

* CEO SAYS SANDOZ EXITING PARTS OF AFRICA WHERE COMPANY IS NOT POSITIONED TO COMPETE

* CEO SAYS DOES NOT EXPECT DEATH IN ZOLGENSMA TRIAL TO IMPACT FDA REGULATORY DECISION

* CEO SAYS DEATH HAPPENED IN DECEMBER, JANUARY TIME FRAME, DECISION FROM AUTHORITIES WAS 'NO CHANGE' TO CLINICAL TRIAL

* CEO SAYS CHILD DEATH IN ZOLGENSMA TRIAL DOES NOT CHANGE SAFETY PROFILE OF ZOLGENSMA

* CEO SAYS U.S. PRICING PRESSURE IMPACTED SANDOZ RESULTS

* CEO SAYS GOAL IS TO FOCUS ON BOLT-ON M&A

* CEO SAYS WRITEOFF OF EMA401 MOLECULE WAS MAIN DRIVER OF Q1 IMPAIRMENT Source text for Eikon: Further company coverage: (Reporting by John Miller)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below